Alumis
Immunology & Inflammation Therapeutics
$240Mtotal raised · 4 rounds on record
3open roles
$40Mlatest round · Venture round · Jul 2024 · 2 yr ago
8backers · Foresite Capital, HBM Healthcare Investments
Overview
We are using a precision approach to develop therapies designed to transform the lives of patients with immune-mediated diseases.
Funding and backers
Total raised
$240M
4 rounds on record
Latest round
$40M
Venture round · Jul 2024 · 2 yr ago
Team
174
US Form 5500 (plan participants) · Dec 2024
Hiring now
4
open roles
Backers
8
Foresite Capital, HBM Healthcare Investments
The money's age
Long since its last round
27 months since the last round · hiring slowed
Momentum
25/100
a new city, in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 17, 2024
Raised a round Venture round $40M · SEC Form D
Mar 4, 2024
Raised a round Venture round $129.5M · SEC Form D
Mar 4, 2021
Raised a round Venture round $60M · SEC Form D
Feb 12, 2021
Raised a round Venture round $10.5M · SEC Form D
2021
Founded
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2024 | $40M | — | SEC Form D |
| Venture round | Mar 2024 | $129.5M | — | SEC Form D |
| Venture round | Mar 2021 | $60M | — | SEC Form D |
| Venture round | Feb 2021 | $10.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | ALUMIS INC. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Martin BablerExecutive Officer, DirectorSEC Form D
John SchroerExecutive OfficerSEC Form D
Derrick RichardsonExecutive OfficerSEC Form D
Mark BradleyExecutive OfficerSEC Form D
Sara KleinExecutive OfficerSEC Form D
David GoldsteinExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Foresite Capital 
Omega Funds 
OrbiMed Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
AltruBio. Developing safer, more durable treatments to improve the lives of patients.
About Sorriso Pharmaceuticals Sorriso is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment…
Mirador Therapeutics is a clinical-stage precision medicine company developing therapies for immune-mediated inflammatory and fibrotic…
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory…
SFA Therapeutics is developing a next-generation oral immune tolerance therapy for psoriasis. Our investigational approach is designed to…
ImmuneSensor Therapeutics | Harnessing the innate immune system to treat inflammation, autoimmune disease and cancer.
Jobs
$195k – $235k per year · Equity · Remote (United States) · 3+ years exp · PhD · United States
Apply
$200k – $250k per year · Equity · In office · 5+ years exp · PhD · South San Francisco
Apply
≈ $159k – $279k per year (Estimated) · Equity · In office · 5+ years exp · PhD · South San Francisco
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$243k
Typical range
$235k – $250k
Open positions
2
2
Jobs
Middle
50%
Architect
50%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Middle | 1 | $235k | $235k |
| Architect | 1 | $250k | $250k |
Highest paying role
Director, Medical Affairs
$250k
Normalized to USD per year
Growth
Hiring Momentum
49/100
Stable
Open positions
4
0 opened / 1 closed in 30 days
Median time-to-fill
154 days
faster than 7% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
67% ▼
Marketing
33% ▼
Activity Timeline
New location: United States
Oct 2026
Added Microsoft Office to stack
Sep 2026
People
Martin Babler
Executive Officer, Director
John Schroer
Executive Officer
Derrick Richardson
Executive Officer
Mark Bradley
Executive Officer
Sara Klein
Executive Officer
David Goldstein
Executive Officer
Jorn Drappa
Executive Officer
Roy Hardiman
Executive Officer
June Lee
Executive Officer, Director
Richard Gaster
Director
Zhengbin Yao
Director
Sapna Srivastava
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Westlake BioPartnersVia a fund
HBM Healthcare InvestmentsVia a fund
SR OneVia a fund
venBio PartnersVia a fund
Nextech InvestVia a fund
63 portfolio companies: Zymeworks, Vividion Therapeutics (Acquired), Zenith Therapeutics and 60 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
Alumis Inc.
Read more
Report
Alumis to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing ne...
Read more
Report
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
Alumis (ALMS) is back in focus after reporting that envudeucitinib missed primary and secondary endpoints in the Phase 2b LUMUS lupus trial, while a predefined interferon gene signature high subgroup showed stronger clinical responses. That mixed trial re
Read more
Report
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
- LUMUS trial did not meet its primary and secondary endpoints in the overall trial population -- Robust responses in the prespecified subgroup of...
Read more
Report
Alumis and ACELYRIN Announce Amended Merger Agreement
Detailed price information for Alumis Inc (ALMS-Q) from The Globe and Mail including charting and trades.
Read more
Report
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
South San Francisco
South San Francisco
United States
HQ
South San Francisco
3 open roles 1 posted in 90 days 10-50 est. staff $250k Avg Salary
hires for Biotech, Operations